Quantcast

Latest B-cell lymphoma Stories

2014-06-25 08:30:51

MabThera SC offers a faster administration time for patients in Europe while potentially saving valuable time for health systems SAN DIEGO, June 25, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today that the commercial launch of MabThera(®) SC in Europe has triggered a $5 million milestone payment to Halozyme during the second quarter under the License and Collaboration Agreement between Halozyme and Roche. Following the launch of Herceptin(®) SC in...

2014-06-09 14:34:42

Rockefeller University Press A new study in The Journal of Experimental Medicine reveals that a high-risk group of patients with follicular lymphoma could benefit from a novel drug combination. Follicular lymphoma, a B cell lymphoma, is an incurable form of non-Hodgkin lymphoma that is diagnosed each year in 120,000 people worldwide. Follicular lymphoma is characterized by slow and relentless tumor growth with inevitable relapses despite intense chemotherapy. Follicular lymphomas are...

2014-04-24 08:33:54

Patent covers methods of use for small molecule inhibitors in the treatment of NHL, including follicular and diffuse large B-cell lymphomas CAMBRIDGE, Mass., April 24, 2014 /PRNewswire-USNewswire/ -- Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that the U.S. Patent and Trademark Office has granted a notice of allowance for U.S. Patent Application...

2014-03-28 08:26:35

MabThera SC offers a faster administration time for patients in Europe while potentially saving valuable time for health systems SAN DIEGO, March 28, 2014 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today that the European Commission (EC) has approved Roche's new subcutaneous (SC) formulation of MabThera(®)( )(rituximab) for the treatment of patients with follicular lymphoma and diffuse large B-cell lymphoma. Following the approval of Herceptin SC in...

2014-03-25 23:31:01

Researchers say a drug approved for the treatment of relapsed T-cell Non-Hodgkin’s Lymphoma may help people with indolent B-cell varieties, too Raleigh, North Carolina (PRWEB) March 25, 2014 Researchers say a drug approved for the treatment of relapsed T-cell Non-Hodgkin’s Lymphoma may help people with indolent B-cell varieties, too. These findings have just been posted on the Non-Hodgkin’s Lymphoma Center at...

2014-03-22 23:02:28

Researchers say a drug approved for the treatment of relapsed T-cell Non-Hodgkin’s Lymphoma may help people with indolent B-cell varieties, too. Raleigh, NC (PRWEB) March 22, 2014 Scientists studying the Non-Hodgkin’s Lymphoma drug Zolinza (vorinostat) say it may improve outcomes for patients fighting indolent B-cell lymphomas like follicular lymphoma and mantle cell lymphoma. The Phase II study, published in the British Journal of Haematology and reported by the Non-Hodgkin’s...

2014-03-17 23:23:11

Scientists say patients with certain forms of aggressive Non-Hodgkin’s Lymphoma are more likely to survive if they respond well to their first treatment. Raleigh, NC (PRWEB) March 17, 2014 An article published in the journal Cancer and reported by the Non-Hodgkin’s Lymphoma Center sheds new light on the prognosis for patients with certain forms of Non-Hodgkin’s Lymphoma. Doctors with the James Comprehensive Cancer Center at Ohio State University focused on two specific subtypes of...

2014-03-10 23:24:25

Targeted drug aims to address high recurrence and lower survival in people with B-cell cancers. Raleigh, NC (PRWEB) March 10, 2014 The Non-Hodgkin’s Lymphoma Center is reporting on new published research on an experimental Non-Hodgkin’s Lymphoma drug that appears to boost the power of existing medications. SNS01-T is a mixture of nanoparticles designed to interfere with the inner workings of malignant B-cells in patients with Non-Hodgkin’s Lymphoma and other B-cell cancers. A new...

2014-03-09 23:01:39

Two new studies in major medical journals may help doctors understand how Non-Hodgkin’s Lymphoma starts, and predict treatment outcomes. Raleigh, NC (PRWEB) March 09, 2014 The Non-Hodgkin’s Lymphoma Center is reporting on new research suggesting that overweight Non-Hodgkin’s Lymphoma patients are just as likely to respond well to treatment as patients with lower BMIs. The report, published in the Annals of Oncology, is one of two new Non-Hodgkin’s Lymphoma risk studies....

2014-03-01 23:01:46

Korean researchers say a combination of techniques improves diagnostic accuracy for several types of Non-Hodgkin’s Lymphoma. Raleigh, NC (PRWEB) March 01, 2014 The Non-Hodgkin’s Lymphoma Center is reporting on encouraging new research published in a medical journal called Diagnostic Cytopathology. Researchers from Yonsei University College of Medicine compared the diagnostic accuracy of two cell testing techniques and found that, when used together, they make it possible to not only...


Word of the Day
snash
  • To talk saucily.
  • Insolent, opprobrious language; impertinent abuse.
This word is Scots in origin and probably imitative.